skip to main |
skip to sidebar
Metabasis Therapeutics : Extension of Its Collaboration with Merck & Co., Inc. to Develop AMPK Activators for Diabetes and Other Metabolic Diseases
April 23, 2008--Metabasis Therapeutics, Inc. (Nasdaq:MBRX) today announced an extension to the sponsored research term under its collaboration with Merck & Co., Inc. for an additional year, through June 2009.
The two companies will continue their joint efforts to identify novel small molecule therapeutics with the potential to treat several diseases, including type 2 diabetes and other metabolic diseases, by activation of an enzyme called AMP-activated Protein Kinase (AMPK). AMPK is thought to play an important role in regulating carbohydrate and fat metabolism and consequently in metabolic diseases such as type 2 diabetes... Metabasis' Press Release -
April 23, 2008--Metabasis Therapeutics, Inc. (Nasdaq:MBRX) today announced an extension to the sponsored research term under its collaboration with Merck & Co., Inc. for an additional year, through June 2009.
The two companies will continue their joint efforts to identify novel small molecule therapeutics with the potential to treat several diseases, including type 2 diabetes and other metabolic diseases, by activation of an enzyme called AMP-activated Protein Kinase (AMPK). AMPK is thought to play an important role in regulating carbohydrate and fat metabolism and consequently in metabolic diseases such as type 2 diabetes... Metabasis' Press Release -
